Adoptive T cell therapy using CA-125-directed chimeric antigen receptors has also been developed for ovarian cancer [13], and a phase I trial has been proposed [14], but no further information or clinical benefit has been reported. This evidence concerns the gene MUC16 and ovarian cancer.